Key result
Bortezomib-lenalidomide-dexamethasone linked to hypersensitivity myocarditis at 19 days that resolves with corticosteroids.
Why the study?
Drug-induced myocarditis is a rare but serious complication of cancer treatments such as lenalidomide and bortezomib, requiring awareness for early diagnosis and treatment.
Does discontinuation of chemotherapy and high-dose corticosteroids improve outcomes in a patient with lenalidomide/bortezomib-induced hypersensitivity myocarditis?
Case Report (n=1)
Does discontinuation of chemotherapy and high-dose corticosteroids improve outcomes in a patient with lenalidomide/bortezomib-induced hypersensitivity myocarditis?
Highlights the rare but severe complication of hypersensitivity myocarditis associated with lenalidomide/bortezomib therapy and the importance of prompt recognition and corticosteroid treatment.
Answers are grounded in this paper and cite their sources.
Alerts clinicians to monitor for myocarditis during bortezomib-lenalidomide-dexamethasone therapy; leaves open optimal management strategies.
Background: Drug-induced myocarditis is a rare complication of certain cancer treatments, characterized by the development of myocardial inflammation shortly after initiation of treatment, potentially leading to heart failure and/or malignant arrhythmias. The development of eosinophilic myocarditis after administration of lenalidomide has been described and bortezomib has been associated with the development of cardiomyopathies and atherosclerosis. Case summary: A 69-year-old woman, recently diagnosed with multiple myeloma underwent local radiotherapy for a pathological fracture of the 4th lumbar vertebra and was treated with bortezomib-lenalidomide-dexamethasone. Within 19 days after therapy initiation, she presented with gastrointestinal symptoms, an erythematous pruritic rash, and general fatigue. Surprisingly, routine electrocardiogram (ECG) showed upwardly concave ST-elevation in I and aVL and ST-depressions in II, III, and aVF. Troponin levels were markedly elevated to 5470 ng/L. Complete blood count revealed eosinophilia. Based on further cardiac work-up, including echocardiography, coronary angiography, and cardiac magnetic resonance imaging (MRI) showing positive T2 imaging and patchy subepicardial late gadolinium enhancement, she was diagnosed with hypersensitivity myocarditis. Additional endomyocardial heart biopsy did not reveal any abnormalities, probably due to sampling error. After discontinuation of chemotherapy and prompt treatment with high doses of corticosteroids, the patient recovered. Discussion: Diagnosis of drug-induced myocarditis can be challenging and even long known widely used (chemo)therapy should be considered a potential trigger. Early diagnosis and treatment are crucial, warranting alertness for suggestive symptoms. Cardiac biomarkers, ECG monitoring, and cardiac MRI are key to confirm the diagnosis. In patients with preserved left ventricular systolic function, two-dimensional speckle tracking echocardiography can provide additional diagnostic information. Every patient presenting with eosinophilia and/or acute onset of auto-immune symptoms after initiation of therapy with lenalidomide/bortezomib deserves prompt cardiac screening. The gold standard remains an endomyocardial biopsy, although sampling error may occur.
No takes yet. Share an insight, caveat, or question.
Verbesselt et al. (2022) conducted a case report in Multiple myeloma (n=1). bortezomib-lenalidomide-dexamethasone was evaluated on Hypersensitivity myocarditis. A 69-year-old woman developed hypersensitivity myocarditis 19 days after initiating bortezomib-lenalidomide-dexamethasone therapy for multiple myeloma, resolving with corticosteroids.
Synapse has enriched 10 related papers. Consider them for comparative context: